Orforglipron
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Eli Lilly · Phase 1 · Recruiting · Enrollment 104
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Investigational Drug: IBI3042 (Part A) | n/r | n/r | n/r | n/r | n/r |
| Investigational Drug: IBI3042 (Part B) | n/r | n/r | n/r | n/r | n/r |
| Matching Placebo (Part B) | n/r | n/r | n/r | n/r | n/r |
| Orforglipron (Part B) | n/r | n/r | n/r | n/r | n/r |
| Matching Placebo (Part A) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.